BiotechTube
AllRock Bio

AllRock Bio

Boston, United States· Est.
allrockbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

AllRock Bio is an early-stage biotech company founded in 2024 by veterans of CinCor Pharma, which was acquired by AstraZeneca for up to $1.8 billion. The company is focused on the development of small molecule therapies for serious cardiopulmonary and fibrotic diseases, including pulmonary hypertension and interstitial lung diseases. Its strategy centers on leveraging its leadership's extensive experience in clinical development, business development, and strategic exits to efficiently advance needed therapies. While currently in a formative, pre-revenue stage, the company's founding team brings a demonstrated history of value creation from asset in-licensing through to successful acquisition.

Pulmonary HypertensionInterstitial Lung DiseasesFibrotic Diseases

Technology Platform

Operational and strategic expertise in identifying, in-licensing, and efficiently developing clinical-stage small molecule therapeutics, rather than a proprietary technological platform.

Funding History

1
Total raised:$50M
Venture$50M

Opportunities

The large, unmet medical need in pulmonary hypertension and interstitial lung diseases presents a significant market opportunity for novel therapies.
The founding team's proven track record of creating value through strategic development and a successful exit (CinCor/AstraZeneca) provides a strong template for attracting investment and partnership deals.
The current biopharma environment favors targeted, capital-efficient developers with deep operational expertise in specific therapeutic areas.

Risk Factors

As a new company, AllRock faces significant asset risk, relying entirely on successfully in-licensing a promising clinical-stage candidate in a competitive landscape.
It is also subject to biotech's inherent clinical development and regulatory risks, as well as financing risk given its pre-revenue status.
The company's strategy is heavily dependent on its small founding team, creating key-person risk.

Competitive Landscape

The cardiopulmonary and fibrotic disease space is highly competitive, with numerous large pharma and biotech companies, including Merck, Boehringer Ingelheim, United Therapeutics, and Gossamer Bio, actively developing therapies. AllRock's primary differentiation is not a novel technology but its leadership's proven operational playbook for efficiently advancing assets to create value for acquisition, competing on execution rather than discovery.

More companies in Small Molecule Drugs →More companies in United States →